![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2020 23:23 | Thanks..I'll regret my all out post in the morning. I know you understand my perspective being Ex-RAF like me. Me and booze have a have a habit of joyfully chatting! :-) | ![]() dovey21 | |
23/4/2020 22:56 | Dovey21, best wishes to your wife and her team. I am a NHS responder and Samaritan volunteer. Important we all do what we can to support the frontline much like the RAF. | ![]() rafboy | |
23/4/2020 22:17 | Yes..sorry! Very unlike me. This crisis strikes a chord. I'm as desperate as many for the 'solution' ? | ![]() dovey21 | |
23/4/2020 22:14 | >> dovey Poignant post! | ![]() nobbygnome | |
23/4/2020 22:13 | Correct. I have put my money where my mouth is but would be saying the same if it was a private company in which I couldn’t buy shares. | ![]() nobbygnome | |
23/4/2020 22:11 | I really didn't expect you to disengage your brain. But I have never seen you so confident in a share. You have in all boards/shares clearly stated your trading approach. But I think you would favour this, over others to pass the trial, irrespective of your holding, feel free to correct me. | ![]() l0ngterm | |
23/4/2020 22:10 | The 400 patients documented in the protocol have been discussed before ad nauseam. The initial study is a pilot in 100 patients and the other 300 are there if they have to proceed to another larger trial. This was confirmed to me by Richard. But also as I have said ad nausam I expect conditional approval on the back of the ongoing trial if the results are good. | ![]() nobbygnome | |
23/4/2020 21:55 | That should read..I believe in the UK and UK scientists. It's the UK that will provide the world with the solution. We're good at solutions...just not good at managing it!! :-)...I'll shut up now..cabin fever and wine! :-) | ![]() dovey21 | |
23/4/2020 21:54 | Crookie, wonder if the "OR" in the trial protocol gave SNG flexibility in case they couldnt recruit for hosp pt's......which I believe they have achieved. As this is early intervention, it would make perfect sense to provide this to anyone showing early infections or even as preventive measure for "at risk" ? small battery nebuliser designed for use at home /nursing homes....anywhere. | ![]() 141jaffa | |
23/4/2020 21:42 | Gilead antiviral drug remdesivir flops in first COVID trialhttps://www.goo | spqstrader | |
23/4/2020 21:39 | From lse board... Among these IFNs, IFN- ?? was already found to strongly inhibit the replication of other corona viruses, such as SARS-CoV, in cell culture, while IFN-?? and ?? were shown to be less effective in this context [211]. There are evidences that patients with higher susceptibility to develop Acute respiratory distress syndrome (ARDS) show indeed deficiency of IFN- ??. | ![]() likya123 | |
23/4/2020 21:35 | I can’t see results before end of May they need to get it right to ensure no hold up at the next stage. Nobby looking at the link I posted the criteria is the same for all treatments and is in line with WHO scale was this the same for the COPD trials do you think? Assuming they would know the WHO guidelines and fancy their chances that it will meet the criteria to be successful. | ![]() crookie3634 | |
23/4/2020 21:31 | There is clearly a further trial/bolt on to the current one based on Richards interview and the link I provided earlier, suggests a home trial. When will news of that drop? I would expect them to confirm when they have recruited all patients and advise a further announcement of the results in due course. Sounds like there might be other bits to come inbetween. Interest Notts is only on its 3rd patient after 10 days and Birmingham is done in a week. 10 sites 100 patients all recruited by end of April? | ![]() crookie3634 | |
23/4/2020 21:26 | Earliest third week of May but I saw somewhere today the beginning of June was more likely. | ![]() nobbygnome | |
23/4/2020 21:22 | Nobby, very wise except you or anyone else apart from the powers that be know when the results are? You first calculated after 12 weeks but we now all know this has been fast tracked and classified as "urgent" by the NHIR after 2 weeks of the trial starting. We also are seeing what appears to be very fast or even full recruitment of patients already. You also correctly acknowledged earlier today that Richard said in his interview that updates will be given in the intermediate term. "Also interesting that they will update the market with timings of the trial. We can look forward to those announcements" Therefore I think you already agree that results will be much sooner than any of us anticipated and may miss selling a third of your holding which I think will be the very best outcome as ofcourse I believe Synairgen may have very well hit the jackpot of all jackpots here! | ![]() likya123 | |
23/4/2020 21:22 | But just to carry on I don't think it is entirely binary. The COPD trial might produce a positive result even if SG016 doesn't. Plus of course there is the fibrosis drug so SNG is not a one trick pony. | ![]() nobbygnome | |
23/4/2020 21:20 | 3. Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes or a chronic lung condition It’s in this paragraph OR NON-HOSPITALISED looks like it has the scope and Richards interview confirmed it. | ![]() crookie3634 | |
23/4/2020 21:18 | >> Ali Thanks for the praise. It is gratefully received and let's hope that many people are saved by this drug. | ![]() nobbygnome | |
23/4/2020 21:17 | >> L0ngterm My average buy price is about 19p so I intend to sell a third of my holding before the results hopefully in the 80s but will take whatever price I can ultimately. That means I will be running for free and whatever will be will be. I am confident but that doesn't mean I disengage my brain so you just have to take some off the table ahead of the results IMHO | ![]() nobbygnome | |
23/4/2020 21:16 | Longterm , the protocols are going out of the window mate. | ![]() peachie 74 | |
23/4/2020 21:15 | hxxps://ctag-support This is also worth a read, an internalNHS document that contains our treatment. | ![]() crookie3634 | |
23/4/2020 21:13 | Longterm, I would sell all your shares in the morning as don't think this share is for you. Nobby, please do the honours.. | ![]() likya123 | |
23/4/2020 21:13 | I just wanted to say thank you for perhaps the most informative and useful thread I have read for many years - I am no expert in this - I have seen the impact of the virus on a young person and the thought that you could potentially prevent this at home is incredibly. Thank you all - especially Nobby. | ![]() ali g2 | |
23/4/2020 21:12 | TVM Crookie V interesting: This indicates it could be used outside hospitals in the trial: Patients admitted to hospital due to the severity of their COVID-19 disease OR non-hospitalised patients from high-risk co-morbidity groups such as the >65-years of age, or those with hypertension, cardiovascular disease, diabetes or a chronic lung condition This is interesting as it means that the trial is on patients newly diagnosed: Principal exclusion criteria 1. > 24 hours after confirmation of SARS-CoV-2 infection | ![]() toffeeman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions